Canadian Dollar Snaps Losing Streak On Volatile NFP Friday The Canadian Dollar caught a much-needed boost against the US Dollar on Friday.
Figma Shares Edge Higher After Explosive IPO Debut, Despite Valuation Concerns Figma shares traded higher on Friday, continuing to draw investor attention after a volatile debut session on Thursday that saw the stock surge over 250% following its initial public offering.
Coinbase Shows Huge Unusual Options Volume After Lower Results Nobody wants to own COIN shares short-term, it seems. After all, its results did not spark a lot of confidence.
Will Hims & Hers Fall Along With Novo Nordisk? Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.
Amazon's Free Cash Flow And FCF Margins Tumble - Is AMZN Overvalued? The market may be realizing that Amazon might not generate strong FCF for a while, as its AI-related spending continues to surge.
Carvana's Comeback Drives These ETFs Into The Limelight—Tariff Tailwinds Add Fuel Carvana's stock (CVNA) has made a dramatic comeback, soaring 11,000%+ to an all-time high and providing opportunities for ETFs to ride the wave.
Novo Nordisk Stock Posts Worst Week Since 2021, But Analysts See A Bigger Problem Ahead Flagship drugs Wegovy and Ozempic face slowing sales due to competition, generics, and U.S. regulatory heat.
What's going on in today's after hours session The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Why Lucid Group Stock Sank This Week Can the EV maker follow its uphill path to profitability?
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank? Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Why Fulgent Genetics Stock Was Crushing It on Friday The next-generation diagnostics specialist had a beat-and-raise second quarter.
